TARSUS PHARMACEUTICALS INC (TARS)
NASDAQ • Healthcare
$71.03
+$0.42 (+0.6%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About TARSUS PHARMACEUTICALS INC
Name
TARSUS PHARMACEUTICALS INC
CEO
Bobak R. Azamian
Website
Industry
Healthcare
Year Founded
2016
Employees
370
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a biotechnology company developing lotilaner-based medicines, centered mainly on ocular disease while extending into dermatology and infectious-disease uses. In FY2025, it recorded $451.4 million in revenue. Its work is organized around investigational therapies for blepharitis, rosacea, Lyme disease prevention, and community-level malaria reduction.
Fundamentals & Financials
Revenue (TTM)
$606.3M
Net Income (TTM)
-$46.4M
EPS (TTM)
-$1.09
ROA (TTM)
-7.6%
Current Ratio
3.2
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$71.03$69.67 - $71.5
52 Week RangeAvg. Volume$48.2 - $85.25782.3K
Market Cap$3B
Peers & Related Assets
CGONCG ONCOLOGY INC
$76.29-1.1%
SRRKSCHOLAR ROCK HOLDING CORP
$54.72+5.1%
TVTXTRAVERE THERAPEUTICS INC
$63.9+0.6%
CELCCELCUITY INC
$93.24+0.9%
ADPTADAPTIVE BIOTECHNOLOGIES CORP
$24.56-0.8%
ARQTARCUTIS BIOTHERAPEUTICS INC
$26.54+3.6%
IRONDISC MEDICINE INC
$80.2+0.2%
LEGNLegend Biotech Corporation
ZLABZai Lab Limited
AAPGAscentage Pharma Group International